B A Teicher

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Alterations in vascular gene expression in invasive breast carcinoma
    Belinda S Parker
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 64:7857-66. 2004
  2. ncbi request reprint Hypoxia, tumor endothelium, and targets for therapy
    Beverly A Teicher
    Adv Exp Med Biol 566:31-8. 2005
  3. ncbi request reprint Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Radiat Oncol Investig 6:71-80. 1998
  4. ncbi request reprint Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Clin Cancer Res 7:634-40. 2001
  5. ncbi request reprint Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Clin Cancer Res 6:1016-23. 2000
  6. ncbi request reprint The proteasome inhibitor PS-341 in cancer therapy
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, Massachusetts 02115, USA
    Clin Cancer Res 5:2638-45. 1999
  7. ncbi request reprint Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 42:24-30. 1998
  8. ncbi request reprint Acute in vivo resistance in high-dose therapy
    B A Teicher
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 4:483-91. 1998
  9. ncbi request reprint Prostate carcinoma response to cytotoxic therapy: in vivo resistance
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA, USA
    In Vivo 11:453-61. 1997
  10. ncbi request reprint Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts
    Beverly A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Invest New Drugs 20:241-51. 2002

Collaborators

Detail Information

Publications57

  1. ncbi request reprint Alterations in vascular gene expression in invasive breast carcinoma
    Belinda S Parker
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 64:7857-66. 2004
    ..Together, our results provide unique insights into vascular regulation in breast tumors and suggest specific roles for genes in driving tumor angiogenesis...
  2. ncbi request reprint Hypoxia, tumor endothelium, and targets for therapy
    Beverly A Teicher
    Adv Exp Med Biol 566:31-8. 2005
    ....
  3. ncbi request reprint Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Radiat Oncol Investig 6:71-80. 1998
    ..This treatment combination also nearly ablated lung metastases on day 20 in these animals. These results may serve as a useful guide in developing clinical protocols, including rmIL-12 and fractionated radiation therapy...
  4. ncbi request reprint Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Clin Cancer Res 7:634-40. 2001
    ..Treatment with the protein kinase Cbeta inhibitor decreased T98G glioblastoma multiforme angiogenesis and improved treatment outcome with BCNU...
  5. ncbi request reprint Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Clin Cancer Res 6:1016-23. 2000
    ..Administration of MTA along with paclitaxel or doxorubicin resulted in additive MX-1 TGD. Thus, MTA appears to be especially effective in combination therapies including 5-fluorouracil or an antitumor platinum complex...
  6. ncbi request reprint The proteasome inhibitor PS-341 in cancer therapy
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, Massachusetts 02115, USA
    Clin Cancer Res 5:2638-45. 1999
    ..c. tumor and was highly effective against disease metastatic to the lungs. The proteasome is an interesting new target for cancer therapy, and the proteasome inhibitor PS-341 warrants continued investigation in cancer therapy...
  7. ncbi request reprint Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 42:24-30. 1998
    ....
  8. ncbi request reprint Acute in vivo resistance in high-dose therapy
    B A Teicher
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 4:483-91. 1998
    ..High-dose combination regimens required dose reduction of the drugs, which resulted in decreased tumor growth delays...
  9. ncbi request reprint Prostate carcinoma response to cytotoxic therapy: in vivo resistance
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA, USA
    In Vivo 11:453-61. 1997
    ..These results support the hypothesis that the drug resistance of prostate carcinoma is manifest in vivo, and that in vivo high levels of TGF-beta may protect these tumors from cytotoxic cancer therapies...
  10. ncbi request reprint Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts
    Beverly A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Invest New Drugs 20:241-51. 2002
    ..8-fold increase in lifespan compared with carboplatin alone. 317615 x 2HCl is a promising new antiangiogenic agent that is in early phase clinical testing...
  11. ncbi request reprint Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 48:473-80. 2001
    ..2HCl was administered along with or sequentially with paclitaxel or carboplatin were much more effective than the chemotherapeutic agents administered alone. 317615.2HCl is in early clinical testing...
  12. ncbi request reprint Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts
    B A Teicher
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Anticancer Res 21:3175-84. 2001
    ..317615 x 2HCl is in early clinical testing...
  13. ncbi request reprint Antiangiogenic effects of a protein kinase Cbeta-selective small molecule
    Beverly A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 49:69-77. 2002
    ..Protein kinase C frequently plays a central role in the intracellular signal transduction of growth factors and cytokines...
  14. ncbi request reprint Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA TEICHER BEVERLY
    In Vivo 15:185-93. 2001
    ..2HCl and to 43 days with the sequential treatment regimen. Treatment with the protein kinase C beta inhibitor 317615.2HCl decreased HS746T and Hep3B angiogenesis and improved treatment outcome with 5-fluorouracil and gemcitabine...
  15. ncbi request reprint Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    In Vivo 14:471-80. 2000
    ..Cryptophycins have the potential to be useful chemotherapeutic agents in a wide variety of clinical combinations regimens...
  16. ncbi request reprint PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    In Vivo 11:301-11. 1997
    ....
  17. ncbi request reprint Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
    B A Teicher
    Dana Farber Cancer Institute, Boston, Massachusetts 02115
    Cancer Res 52:6702-4. 1992
    ..Five of 12 animals treated with the antiangiogenic modulators and cyclophosphamide were long-term survivors (> 120 days). Thus, antiangiogenic therapies can potentiate the efficacy of standard anticancer therapies...
  18. ncbi request reprint Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    Anticancer Res 18:2567-73. 1998
    ....
  19. ncbi request reprint Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo
    A Asea
    Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Int J Hyperthermia 17:347-56. 2001
    ..These experiments, thus, suggest the use of Quercetin as a hyperthermia sensitizer in the treatment of prostate carcinoma...
  20. ncbi request reprint Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells
    K Lu
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 47:170-8. 2001
    ..The cryptophycins were more potent cytotoxic agents in Bcl-2-negative Calu-6 cells than in Bcl-2-positive H460 cells indicating that pathways triggered by Bcl-2 phosphorylation are involved in cryptophycin-induced lethality...
  21. ncbi request reprint A carbonic anhydrase inhibitor as a potential modulator of cancer therapies
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA 02115
    Anticancer Res 13:1549-56. 1993
    ..The mechanism may involve its ability to acidify the intratumoral environment, but other mechanisms can not be excluded...
  22. ncbi request reprint beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA 02115
    Cancer Chemother Pharmacol 33:229-38. 1993
    ..These results indicate that agents that inhibit the breakdown of the extracellular matrix can be useful additions to the treatment of solid tumors...
  23. ncbi request reprint Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype
    G Chen
    Dana Farber Cancer Institute, Division of Cancer Pharmacology, Harvard Medical School, Boston, MA 02115, USA
    Cancer Biochem Biophys 16:139-55. 1998
    ....
  24. ncbi request reprint Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial
    R S Herbst
    Division of Adult Oncology, Lowe Cancer Center for Thoracic Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Cancer Chemother Pharmacol 48:151-9. 2001
    ..However, hematologic toxicities, as found in this study, could probably be reduced with treatment on days 1 and 8 every 21 days, and current literature would suggest this to be the preferred schedule...
  25. ncbi request reprint Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II)
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA
    Int J Cancer 47:252-60. 1991
    ..These results indicate that cellular resistance to CDDP often involves decreases in drug accumulation and increases in protein sulfhydryl content. Possible strategies for overcoming these mechanisms are discussed...
  26. ncbi request reprint Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation
    S A Holden
    Dana Farber Cancer Institute, Boston, MA 02115
    Radiother Oncol 18:59-70. 1990
    ..6-fold sparing of the dim cell population. Our results indicate that treatment strategies directed against both oxic and hypoxic tumor subpopulations can markedly increase the tumor cell kill achieved by radiation...
  27. ncbi request reprint Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents
    K Lu
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 46:293-304. 2000
    ....
  28. ncbi request reprint Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation
    A Asea
    Department of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Int J Hyperthermia 17:401-14. 2001
    ..01) inhibition of hyperthemia-induced serum prostaglandin E2. These findings indicate that NSAID may have both sensitizing effects on prostate tumour growth and may function by inhibiting prostaglandin synthesis...
  29. ncbi request reprint Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo
    B A Teicher
    Dana Farber Cancer Institute, Boston, Massachusetts 02115
    Cancer Res 49:5994-8. 1989
    ..In conclusion, for all six alkylating agents examined, the multiple dose schedule was at least as effective against the tumor as the single dose schedule at all dose levels...
  30. ncbi request reprint Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker
    M Nozue
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Surg Oncol 66:30-8. 1997
    ..These results were also compared to the immunohistochemical staining of 2-nitromidazole adducts...
  31. ncbi request reprint Malignant cells, directors of the malignant process: role of transforming growth factor-beta
    B A Teicher
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Metastasis Rev 20:133-43. 2001
    ..Cancer cure may be approached by blocking several of the major normal pathways used for tumor growth and survival in combination with cytotoxic therapies...
  32. ncbi request reprint Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides
    C Shih
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Pharm Des 7:1259-76. 2001
    ..Cryptophycin 52 is currently in early clinical testing...
  33. ncbi request reprint Effect of hypoxia and acidosis on the cytotoxicity of mitoxantrone, bisantrene and amsacrine and their platinum complexes at normal and hyperthermic temperatures
    T S Herman
    Dana Farber Cancer Institute, Boston, MA 02115
    Anticancer Res 12:827-36. 1992
    ..45 versus pH 7.40, although this finding did not correlate with cytotoxicity. These results suggest that PtCl4(MITOX)2 and PtCl4(m-AMSA)2 may be highly interactive drugs with local hyperthermia...
  34. pmc 1,2-dithiol-3-thione and dithioester analogues: potential radioprotectors
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA 02115
    Br J Cancer 62:17-22. 1990
    ..0 and 1.6, respectively. These results demonstrate that several of these compounds are highly effective radioprotectors. In vitro and in vivo studies testing their efficacy are underway...
  35. pmc Platinum-dye complexes inhibit repair of potentially lethal damage following bleomycin treatment
    Y Wang
    Dana Farber Cancer Institute, Boston, MA
    Br J Cancer 59:722-6. 1989
    ..These results indicate that several of the new platinum complexes may be effective cytotoxic agents as well as effective inhibitors of DNA repair process following exposure of cells to other DNA interactive modalities...
  36. ncbi request reprint Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro
    K W Rosbe
    Dana Farber Cancer Institute, Boston, MA 02115
    Cancer Chemother Pharmacol 25:32-6. 1989
    ..Therefore, when lonidamine was present during exposure to the alkylating agent and its presence was then extended for an additional 12 h, a synergistic cell kill was produced with all four alkylating agents tested...
  37. ncbi request reprint Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Microvasc Res 71:163-74. 2006
    ..Pericytes displayed invasive action against NSCLC clusters in the absence of other cell types. Perivascular cells contribute to the progression of disease and are an attractive target for anti-angiogenic therapy...
  38. ncbi request reprint Newer vascular targets: endosialin (review)
    Beverly A Teicher
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 30:305-12. 2007
    ..The selective expression of endosialin by tumor vasculature and stroma has been confirmed. Although the function of endosialin remains to be elucidated, the expression pattern for this protein may be favorable for cancer therapy...
  39. ncbi request reprint LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice
    Kristan A Keyes
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 53:133-40. 2004
    ..Plasma VEGF was a weak marker of response to LY317615, and plasma bFGF and TGFbeta were not markers of LY317615 activity...
  40. ncbi request reprint Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model
    Jennifer Walter-Yohrling
    Department of Tumor Biology, Genzyme Molecular Oncology, Genzyme Corporation, Five Mountain Road, Framingham, MA 01701, USA
    Cancer Chemother Pharmacol 52:263-9. 2003
    ..In an effort to study the importance of stromal involvement in angiogenesis, we developed a novel, multicellular model that utilizes three of the primary cell types involved in tumor angiogenesis...
  41. ncbi request reprint Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology
    Kristan A Keyes
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cancer Chemother Pharmacol 51:321-7. 2003
    ....
  42. ncbi request reprint An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy
    Kristan Keyes
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Cancer Res 62:5597-602. 2002
    ..Although malignant cells alone secreted VEGF, stromal cells secreted TGF-beta and bFGF at levels comparable with or greater than malignant cells and thus may be important contributors to tumor growth and progression...
  43. ncbi request reprint Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy
    Rebecca G Bagley
    Genzyme Corp, Framingham, Massachusetts 01701 9322, USA
    Cancer Res 65:9741-50. 2005
    ..These results support the notion that pericytes and EPC contribute to malignancy and that these cell types can be useful as cell-based models for tumor vascular development and selection of agents that may provide therapeutic benefit...
  44. ncbi request reprint Transforming growth factor-beta and the immune response to malignant disease
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 13:6247-51. 2007
    ..Phase I clinical trials of an inhibitor of TGF-beta receptor type I kinase activity and a TGF-beta neutralizing antibody are under way...
  45. ncbi request reprint Tumor models for efficacy determination
    Beverly A Teicher
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA
    Mol Cancer Ther 5:2435-43. 2006
    ..Each of these types of models has advantages and disadvantages to the "drug hunter" searching for improved treatments...
  46. ncbi request reprint Protein kinase C as a therapeutic target
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 12:5336-45. 2006
  47. doi request reprint Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination
    Kent Perry
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Urology 72:225-9. 2008
    ..The present study was conducted to determine whether removal of TGF-beta from these tumor cells would inhibit tumor progression in vivo...
  48. ncbi request reprint TGF-beta in cancer and as a therapeutic target
    Jan Pinkas
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01721, United States
    Biochem Pharmacol 72:523-9. 2006
    ..Transforming growth factor-beta and its receptors are targets for antibody therapeutics and small molecule kinase inhibitors...
  49. ncbi request reprint Tumor models for preclinical development of targeted agents
    Beverly A Teicher
    Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA
    Prog Drug Res 63:43-66. 2005
  50. ncbi request reprint Assays for in vitro and in vivo synergy
    Beverly A Teicher
    Genzyme Corporation, Framingham, MA, USA
    Methods Mol Med 85:297-321. 2003
  51. ncbi request reprint Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells
    Rebecca G Bagley
    Genzyme Corp, Framingham, Massachusetts 01701 9322, USA
    Cancer Res 63:5866-73. 2003
    ..EPC may be a better model of human tumor endothelial cells than HUVEC and HMVEC and, thus, may provide an improved cell-based model for second generation antineoplastic antiangiogenic drug discovery...
  52. ncbi request reprint Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption
    Enrique Alvarez
    Lilly Research Laboratories, Indianapolis, Indiana St Vincent s Institute of Medical Research, Melbourne, Fitzroy, Australia
    Clin Cancer Res 9:5705-13. 2003
    ..The results of this study demonstrate the ability of 13762 rat mammary carcinoma cells to elicit a measurable osteolysis and that bisphosphonates inhibit the tumor-induced bone resorption in this model...
  53. ncbi request reprint Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring
    Donald M McDonald
    University of California at San Francisco, San Francisco, CA, USA
    J Immunother 27:161-75. 2004
    ..The third addressed the translation to the clinic and monitoring of antiangiogenic activity of agents in patients and novel trial designs. What follows is a summary of the discussions and findings of each session...
  54. ncbi request reprint Murine endothelial cell lines as models of tumor endothelial cells
    Jennifer Walter-Yohrling
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 10:2179-89. 2004
    ..These cells can be used in in vitro angiogenesis assays for evaluating the potential antiangiogenic properties and interspecies cross-reactivity of novel compounds...
  55. pmc Vascular gene expression in nonneoplastic and malignant brain
    Stephen L Madden
    Genetics and Genomics, 5 Mountain Rd, Framingham, MA 01701, USA
    Am J Pathol 165:601-8. 2004
    ..Additional characterization of this extensive brain endothelial cell gene expression database will provide unique molecular insights into vascular gene expression...
  56. ncbi request reprint Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions
    Giampietro Gasparini
    Division of Medical Oncology, S Filippo Neri Hospital, Rome, Italy
    J Clin Oncol 23:1295-311. 2005
    ....
  57. ncbi request reprint Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Cancer Ther 7:2536-46. 2008
    ..The data presented here on endothelial genes that are up-regulated in tumor vasculature and in EPC support the hypothesis that the angiogenesis process in cancer can involve EPC...